Calgary, AB, Canada Clinical Trials

A listing of Calgary, AB, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 513 clinical trials
featured
Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy

The purpose of this study is to determine whether FT218 is safe and effective for the treatment of excessive daytime sleepiness and cataplexy in subjects with narcolepsy.

somnolence
sodium oxybate
cataplexy
multiple sleep latency test
stimulant
Somni Research Inc. Calgary
 (9.6 away) Contact site
  • 23 views
  • 10 Jul, 2018
  • +52 other locations
featured
C2541013 MIRNA NASH  

The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor). This study is specifically designed to evaluate the effect of a range of doses of DGAT2i alone, and DGAT2i + ACCi, on resolution of NASH or improvement …

University of Calgary
 (3.0 away)
  • 275 views
  • 30 Jul, 2021
  • +64 other locations
featured
ECOSPOR III: A Phase 3 Multicenter, RandomizeEd, Double Blind, Placebo COntrolled, Parallel Group Study to Evaluate the Safety, Tolerability, & Efficacy of SER-109 vs. Placebo to Reduce Recurrence of ClOstRidium Difficile Infection (CDI) in Adults

ECOSPOR III is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the safety, tolerability, and efficacy of SER-109 versus placebo in adult subjects 18 years of age or older with recurrent CDI, defined as: a history of ≥ 3 CDI episodes within 9 months, inclusive of the current …

antibiotics
vancomycin
clostridium difficile
antibiotic therapy
fidaxomicin
Alberta Health Services (AHS) - Foothills Medical Centre (FMC)
 (2.9 away) Contact site
  • 1095 views
  • 21 Dec, 2020
  • +71 other locations
featured
ECOSPOR IV: An Open-Label Extension of Study SERES-012 and Open-Label Program for Evaluating SER-109 in Adult Subjects with Recurrent Clostridioides difficile Infection (RCDI)

ECOSPOR IV is a Phase 3, multicenter, Open Label study to evaluate the safety and tolerability of SER-109 in adult subjects with recurrent CDI.

clostridium difficile
Alberta Health Services (AHS) - Foothills Medical Centre (FMC)
 (2.9 away) Contact site
  • 41 views
  • 21 Dec, 2020
  • +76 other locations
featured
Fox Insight - Online Parkinson's Health and Genetic Study

Fox Insight is an online study gathering health information from tens of thousands of people with and without Parkinson’s disease.  Study participation does not require any travel and all you need is an internet connection to start today at www.foxinsight.org Fox Insight volunteers are invited to take part in virtual …

www.foxinsight.org
 (1.7 away) Contact site
  • 3560 views
  • 29 Mar, 2021
  • +333 other locations
featured
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Research Center
 (2.2 away) Contact site
  • 1940 views
  • 25 Mar, 2021
  • +106 other locations
featured
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 – Canada  

The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements.   This is an interventional active-controlled, open-label, randomized Phase 3 study to compare the efficacy and safety of luspatercept …

epoetin alfa
Tom Baker Cancer Centre
 (2.9 away)
  • 33 views
  • 03 Aug, 2021
  • +9 other locations
featured
INCB 18424-303: Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE-AD1)

A Phase 3, randomized (2:2:1), double-blind, 8-week vehicle control efficacy and safety study of ruxolitinib followed by a randomized, double-blind, 44-week long term safety (LTS) extension period.  In the LTS period,  participants initially randomized to vehicle will receive either ruxolitinib 0.75% or 1.5% cream.  All participants will have follow-up assessments …

eczema
atopic dermatitis/eczema
atopic dermatitis
INSTITUTE FOR SKIN ADVANCEMENT
 (4.6 away) Contact site
  • 246 views
  • 14 Dec, 2020
  • +37 other locations
featured
A Phase 2, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1% Cream–Controlled Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

A Phase 2, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1% Cream–Controlled Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

dermatitis
atopic dermatitis/eczema
atopic dermatitis
INSTITUTE FOR SKIN ADVANCEMENT
 (4.6 away) Contact site
  • 1344 views
  • 08 Dec, 2020
  • +52 other locations
Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease

Individuals receiving dialysis are at risk of heart failure and heart related death. There is an urgent need for treatments that reduce the risk of these problems in patients that require dialysis. Spironolactone is a pill used to prevent heart failure and related deaths in patients that do not require …

Foothills Hospital
 (2.9 away) Contact site
  • 41 views
  • 26 Jan, 2021
  • +97 other locations